NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$8.77

+0.06 (+0.69%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $8.60
▼
$8.89
50-Day Range: $7.77
▼
$10.57
52-Week Range: $3.18
▼
$10.88

Volume: 629,975 shs
Average Volume: 1.09 million shs
Market Capitalization: $764.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.40

Institutional Ownership

Provention Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 144.0% Upside
$21.40 Price Target
Short Interest: Bearish
8.35% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.90
Upright™ Environmental Score
News Sentiment: -0.02
Based on 7 Articles This Week
Insider Trading: Selling Shares
$30.72 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.66) to ($1.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

546th out of 1,055 stocks

Pharmaceutical Preparations Industry

268th out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
Provention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.40, Provention Bio has a forecasted upside of 144.0% from its current price of $8.77.
Amount of Analyst Coverage
Provention Bio has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.35% of the outstanding shares of Provention Bio have been sold short.
Short Interest Ratio / Days to Cover
Provention Bio has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Provention Bio has recently decreased by 1.75%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Provention Bio does not currently pay a dividend.
Dividend Growth
Provention Bio does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Provention Bio has received a 70.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for the autoimmune system" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Provention Bio is -0.90.

1.1

News and Social Media Coverage

News Sentiment
Provention Bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Provention Bio this week, compared to 2 articles on an average week.
Search Interest
Only 23 people have searched for PRVB on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Provention Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Provention Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,723,919.00 in company stock.
Percentage Held by Insiders
13.10% of the stock of Provention Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.39% of the stock of Provention Bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Provention Bio are expected to grow in the coming year, from ($1.66) to ($1.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Provention Bio is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Provention Bio is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Provention Bio has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

January 24, 2023 | finance.yahoo.com

Should You Invest in Provention Bio (PRVB)?

January 22, 2023 | reuters.com

PRVB.OQ - | Stock Price & Latest News | Reuters

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 21, 2023 | americanbankingnews.com

Provention Bio, Inc. (NASDAQ:PRVB) CEO Ashleigh Palmer Sells 24,165 Shares

January 21, 2023 | americanbankingnews.com

Provention Bio, Inc. (NASDAQ:PRVB) Insider Francisco Leon Sells 24,015 Shares of Stock

January 21, 2023 | americanbankingnews.com

Provention Bio, Inc. (NASDAQ:PRVB) Major Shareholder Sessa Capital (Master), L.P. Sells 3,000,000 Shares

January 11, 2023 | finance.yahoo.com

Market Sentiment Around Loss-Making Provention Bio, Inc. (NASDAQ:PRVB)

January 5, 2023 | finance.yahoo.com

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

January 28, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 2, 2023 | seekingalpha.com

Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch

December 28, 2022 | finance.yahoo.com

12 Best Biotech Stocks to Buy Under $10

December 15, 2022 | finance.yahoo.com

While institutions invested in Provention Bio, Inc. (NASDAQ:PRVB) benefited from last week's 7.6% gain, individual investors stood to gain the most

December 5, 2022 | finance.yahoo.com

Why Shares of Provention Bio Went Up 30.3% in November

November 25, 2022 | seekingalpha.com

Provention Bio: Assessing The Investment Case After Teplizumab Approval

November 19, 2022 | msn.com

Provention prices diabetes drug above analysts' estimates at $13,850/vial

November 18, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Provention Bio

November 18, 2022 | finance.yahoo.com

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

November 18, 2022 | finance.yahoo.com

Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes

November 18, 2022 | investorplace.com

Provention Bio (PRVB) Stock Falls Despite FDA Approval

November 18, 2022 | reuters.com

Provention Bio diabetes drug to cost $13,850/vial

November 18, 2022 | reuters.com

U.S. FDA greenlights Provention Bio's diabetes drug

November 4, 2022 | seekingalpha.com

Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript

November 3, 2022 | investorplace.com

Why Is Provention Biosciences (PRVB) Stock Up 25% Today?

November 3, 2022 | msn.com

Provention Bio: Q3 Earnings Insights

October 13, 2022 | finance.yahoo.com

Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022

October 12, 2022 | finance.yahoo.com

These 2 Growth Stocks Have Potential Catalysts on the Way

October 6, 2022 | benzinga.com

Thinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings: 11/03/2022
Today: 1/27/2023
Next Earnings (Estimated): 2/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRVB
CUSIP: N/A
CIK: 1695357
Web: www.proventionbio.com
Phone: (908) 428-9136
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.40
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +144.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,430,000.00
Net Margins: -3,791.21%
Pretax Margin: -4,043.30%
Return on Equity: -99.08%
Return on Assets: -76.29%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 7.58
Quick Ratio: 7.58

Sales & Book Value

Annual Sales: $1.39 million
Price / Sales: 550.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.75 per share
Price / Book: 5.01

Miscellaneous

Outstanding Shares: 87,191,000
Free Float: 75,769,000
Market Cap: $764.67 million
Optionable: Not Optionable
Beta: 2.29

Key Executives

Ashleigh W. Palmer
Chief Executive Officer & Director

Christina Yi
Chief Operating Officer

Thierry Chauche
Chief Financial Officer

Francisco Leon
Chief Scientific Officer

Eleanor Leni Ramos
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings or view top-rated stocks.
What is Provention Bio's stock price forecast for 2023?: 6 Wall Street research analysts have issued 12 month price targets for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they expect the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price.
View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts.
How have PRVB shares performed in 2023?: Provention Bio's stock was trading at $10.57 at the start of the year. Since then, PRVB shares have decreased by 17.0% and is now trading at $8.77.
View the best growth stocks for 2023 here.
When is Provention Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRVB earnings forecast.
How were Provention Bio's earnings last quarter?: Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.12. The firm earned $0.76 million during the quarter, compared to analyst estimates of $0.88 million. Provention Bio had a negative net margin of 3,791.21% and a negative trailing twelve-month return on equity of 99.08%.

What other stocks do shareholders of Provention Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).
What is Provention Bio's stock symbol?: Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."
Who are Provention Bio's major shareholders?: Provention Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.21%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP.
View institutional ownership trends.
How do I buy shares of Provention Bio?: Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Provention Bio's stock price today?: One share of PRVB stock can currently be purchased for approximately $8.77.
How much money does Provention Bio make?: Provention Bio (NASDAQ:PRVB) has a market capitalization of $764.67 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.
How can I contact Provention Bio?: Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 1/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Provention Bio - PRVB Stock Forecast, Price & News

Provention Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Provention Bio (NASDAQ:PRVB) Stock

PRVB Stock News Headlines

PRVB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRVB Stock - Frequently Asked Questions

Overall MarketRank^™